Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance

McDonald, Andrew M.; Lindeman, Brenessa; Bahl, Deepti

doi:10.1200/jco.22.00013

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study utilizing Surveillance, Epidemiology, and End Results (SEER) data included DTC patients for a total of 13 years from 1988 to 2001 (n = 18,882) and reported that RAI treatment was not associated with an increased risk of SPM [20]. Therefore, it is important to recognize the need for risk-benefit balance for DTC patients treated with RAI [21]. Previous studies using SEER tend to have a small sample size, short research time, or short follow-up time [4,10].…”

Section: Discussionmentioning

confidence: 99%

Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study

et al. 2023

Endokrynol Pol

View full text Add to dashboard Cite

thyroid cancer is excellent. RAI therapy plays an important role in reducing the risk of disease recurrence and tumour-related death, as well as good prognosis. Despite a favourable prognosis, the scope of treatment for many patients with thyroid cancer is controversial, including the extent of surgery as well as the use and dose of RAI therapy [6][7][8]. The side effects of RAI treatment are considered minimal, but RAI may cause some acute or chronic effects [5]. Moreover, the most important concern is whether RAI will benefit survival and increase potential risk of second primary malignancy (SPM) [9,10]. Studies have shown that 19% of patients develop second malignancy after surviving a primary carcinoma [11]. The reasons include continued lifestyle, genetic susceptibility, and treatment modality (radiotherapy and chemotherapy) [12][13][14]. It is difficult to estimate the incidence of second primary ma-

show abstract

Section: Discussionmentioning

confidence: 99%

Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study

et al. 2023

Endokrynol Pol

View full text Add to dashboard Cite

show abstract

Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview

Singh,

Ramamourthy,

Hage

et al. 2024

CRP

View full text Add to dashboard Cite

Thyroid cancer is the fifth most prevalent cancer in women and the fastest-growing malignancy. Although surgery is still the basis of treatment, internal radiation therapy [Brachytherapy] with radioactive iodine-131, which functions by releasing beta particles with low tissue penetration and causing DNA damage, is also a potential option. The three basic aims of RAI therapy in well-differentiated thyroid tumors are ablation of the remnant, adjuvant therapy, and disease management. Radioactive iodine dose is selected in one of two ways, empiric and dosimetric, which relies on numerous criteria. The dosage for ablation is 30-100 mCi, 30-150 mCi for adjuvant therapy, and 100-200 mCi for treatment. The RAI treatment effectively aids in the treatment to achieve complete removal of the disease and increase survival. The present review intends to emphasize the significance of radioactive iodine in the management of differentiated thyroid cancer and put forward the current breakthroughs in therapy.

show abstract

A novel risk stratification model based on tumor size and multifocality to predict recurrence in pediatric PTC: comparison with adult PTC

Du,

Zhang,

Kou

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPediatric papillary thyroid cancer presents with a more advanced stage of disease than adult PTC; and it is more likely to be aggresive and distant metastases, although the survival rate is high.MethodsA retrospective observational study was performed in children and adults with PTC. Fisher’s exact, chi-square, and rank-sum tests were used to examine the differences. Univariate and multivariate Cox regression analyses were applied to determine the possible risk factors for prognosis. A Kaplan-Meier curve analysis was performed to investigate the relationship between the clinicopathological characteristics and recurrence rate.ResultsThe study involved 156 children and 1,244 adults with PTC. Compared to the group without recurrence, proportions of tumors measuring > 1 cm (48.3% vs. 90.9%) and multifocality (30.3% vs. 63.6%) were higher, N1b stage occurred more frequently (33.8% vs. 100%). However, among adult PTC patients, those with recurrence were older (76.1% vs. 59.4%) than those without recurrence. Risk factors for pediatric PTC recurrence included tumor size and multifocality. However, in adult PTC, the risk factor was LLNM. The newly constructed Stratification.N showed better performance, as illustrated by the fact that patients who were classified into Stratification.N 3 showed an obviously poorer prognosis (P=0.01 and P=0.00062), especially in those aged >14 years (P=0.0052).ConclusionCompared with adult PTC, pediatric PTC showed unique characteristics in terms of clinical pathology and recurrence. Tumor size and multifocality were strong risk factors for pediatric PTC. Accordingly, the novel proposed risk stratification method could effectively predict the recurrence of pediatric PTC.

show abstract

Radioactive Iodine: Recognizing the Need for Risk-Benefit Balance

Cited by 3 publications

References 19 publications

Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study

Hazard ratios of second primary malignancy after radioiodine for differentiated thyroid carcinoma: a large-cohort retrospective study

Radioactive Iodine in Differentiated Carcinoma of Thyroid: An Overview

A novel risk stratification model based on tumor size and multifocality to predict recurrence in pediatric PTC: comparison with adult PTC

Contact Info

Product

Resources

About